VXM01 vaccine in progressive glioblastoma: final results

VXM01 is an orally-administered vaccine that elicits a systemic T-cell response targeting VEGFR-2. Here, Wolfgang Wick, MD, from the German Cancer Research Center, Heidelberg, Germany, discusses the r... Author: VJOncology Added: 08/21/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts